Compounds > n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
Page last updated: 2024-09-03

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and 1-methyl-3-isobutylxanthine

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with 1-methyl-3-isobutylxanthine in 1 studies

Compound Research Comparison

Studies
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)		Trials
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)		Recent Studies (post-2010)
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)		Studies
(1-methyl-3-isobutylxanthine)		Trials
(1-methyl-3-isobutylxanthine)		Recent Studies (post-2010) (1-methyl-3-isobutylxanthine)
2145585,1485279

Protein Interaction Comparison

ProteinTaxonomyn(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50)1-methyl-3-isobutylxanthine (IC50)
Chain A, High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)8.1
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)31
Chain A, Phosphodiesterase 9AHomo sapiens (human)500
Chain A, Class I phosphodiesterase PDEB1Leishmania major580
Chain A, High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)698
Chain A, cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)40
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)117.2
Chain A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)117.2
Phosphodiesterase Bos taurus (cattle)9.9
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)4
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)3.1667
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)9.9
Adenosine receptor A1Rattus norvegicus (Norway rat)7
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)3.4
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)9.9
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)3.4
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BRattus norvegicus (Norway rat)0.1
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)0.242
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)3.4
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)7
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CRattus norvegicus (Norway rat)0.1
Phosphodiesterase Rattus norvegicus (Norway rat)0.1

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahn, S; Cheong, JH; Jacobson, KA; Jeong, LS; Jin, SH; Kim, G; Kim, HJ; Kim, J; Lee, E; Lee, M; Noh, M; Yu, J1

Other Studies

1 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and 1-methyl-3-isobutylxanthine

ArticleYear
Polypharmacology of N
    Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17

    Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adiponectin; Animals; Cell Line; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Mice; Mice, Inbred C57BL; Polypharmacology; PPAR delta; PPAR gamma; Receptor, Adenosine A3

2017